Clinical trial · Observational
Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy
NCT02407977CI-TRIAL-00035387completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study. This protocol will determine the feasibility of using a novel nano-material based fiber-optic dosimeter (nanoFOD) device, with dimensions less than 1 mm wide, to measure real-time, pin-point, in-vivo radiation dose given during external beam delivery of radiation therapy treatments.This new protocol is similiar in design to Pro00050297 with the significant difference being the monitoring will be performed during external baem radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Gastrointestinal, Genitourinary or Gynecologic Systems | Malignant Digestive System Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Dosimetric accuracy of the device with reference to a commercially available dosimeter
- timeFrame
- 24 months
Secondary outcomes (1)
- measure
- Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.
- timeFrame
- 24 months
- description
- Feasibility in this context will mean ease of clinical use (subjective) and lack of device failures.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented neoplasm of the pelvis (including gynecologic, gastrointestinal, and genitourinary origin). * Planned external beam radiotherapy as part of standard of care treatment * The radiotherapy plan involves the body surface * Age \> 18 years * Able to provide and execute informed consent Exclusion Criteria: * Allergy or previous intolerance of skin adhesives * Any clinical scenario in which the nanoFOD placement or reading would compromise the treatment efficacy, or endanger the patient in any way.
References
Publications (0)
Data not yet available
No reference posted for this study.